EFTR
Effector Therapeutics Inc
NASDAQ: EFTR · HEALTHCARE · BIOTECHNOLOGY
$0.00
+0.00% today
Updated 2026-06-02
Market cap
$2352.00
P/E ratio
—
P/S ratio
69.65x
EPS (TTM)
$-12.57
Dividend yield
—
52W range
$0 – $0
Volume
0.0M
WallStSmart proprietary scores
34
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$10.00
+1999900.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Revenue growth 117.00% QoQ
Risks
- Thin margins at 0.00%
- Negative free cash flow $-7.28M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|
| Revenue | $42.00M | $1.43M | $3.55M | $0.00 | $675000.00 |
| Net income | $14.21M | $15.80M | $-12.93M | $-35.81M | $-8.83M |
| EPS | — | — | — | — | $-12.57 |
| Free cash flow | $13.68M | $-24.93M | $-26.09M | $-29.65M | $-7.28M |
| Profit margin | 33.84% | 1,104.76% | -363.83% | — | — |
Peer comparison
Smart narrative
Effector Therapeutics Inc trades at $0.00. Our Smart Value Score of 34/100 indicates the stock is weak. TTM revenue stands at $675000.00.
Frequently asked questions
What is Effector Therapeutics Inc's stock price?
Effector Therapeutics Inc (EFTR) trades at $0.00, on a P/S of 69.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Effector Therapeutics Inc overvalued?
Effector Therapeutics Inc carries a Smart Value Score of 34/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Effector Therapeutics Inc (EFTR)?
The 12-month analyst consensus target is $10.00, about 1999900.0% above the current $0.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Effector Therapeutics Inc's revenue?
Effector Therapeutics Inc's trailing twelve-month revenue is $675000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio69.65x
ROE-947.00%
Beta2.42
50D MA$0.00
200D MA$0.00
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—